As part of RegMed XB’s diabetes moonshot, researchers at the Leiden University Medical Center (LUMC) have developed a method to enhance the purity of insulin-producing islets, grown from stem cells in the laboratory. While originally aimed at diabetes, this technique has broader implications and could be applied to various stem cell-based therapies.

Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies. Founded by Prof. Dr. Eva van Rooij and Prof. Dr. Yigal Pinto in 2022, the company has made significant progress with Dr. Margien Boels, PhD, as Chief Operating Officer. 

In October last year, RegMed XB applied for a 3-year Public-Private Partnership (PPS) subsidy program, called 'Regenerative Medicine Translational Synergy'.